The Complex Tail of Circulating Sphingolipids in Atherosclerosis and Cardiovascular Disease
10.12997/jla.2021.10.3.268
- Author:
Iris D. ZELNIK
1
;
Jiyoon L. KIM
;
Anthony H. FUTERMAN
Author Information
1. Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
- Publication Type:Review
- From:Journal of Lipid and Atherosclerosis
2021;10(3):268-281
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sphingolipids (SLs) are critical players in a number of cellular processes and have recently been implicated in a large number of human diseases, including atherosclerosis and cardiovascular disease (CVD). SLs are generated intracellularly in a stepwise manner, starting with the generation of the sphingoid long chain base (LCB), followed by N-acylation of the LCB to form ceramide, which can be subsequently metabolized to sphingomyelin and glycosphingolipids. Fatty acids, which are taken up by cells prior to their activation to fatty acyl-CoAs, are used in 2 of these enzymatic steps, including by ceramide synthases, which use fatty acyl-CoAs of different chain lengths to generate ceramides with different N-acyl chain lengths. Recently, alterations in plasma ceramides with specific N-acyl chain lengths and degrees of saturation have emerged as novel biomarkers for the prediction of atherosclerosis and overall cardiovascular risk in the general population. We briefly review the sources of plasma SLs in atherosclerosis, the roles of SLs in CVD, and the possible use of the “ceramide score” as a prognostic marker for CVD.
